NovoCure Ltd Files Definitive Proxy Statement

TL;DR

<b>NovoCure Ltd has filed its Definitive Proxy Statement for the period ending June 5, 2024.</b>

AI Summary

NovoCure Ltd (NVCR) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. NovoCure Ltd filed a Definitive Proxy Statement (DEF 14A) on April 22, 2024. The filing covers the period ending June 5, 2024. The company's fiscal year ends on December 31. NovoCure Ltd is classified under SIC code 3841 for Surgical & Medical Instruments & Apparatus. The filing includes executive compensation data for the fiscal years 2020 through 2023.

Why It Matters

For investors and stakeholders tracking NovoCure Ltd, this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation, voting matters, and corporate governance before the annual meeting. It provides insights into the company's financial performance and strategic direction as reflected in executive incentives and proposals.

Risk Assessment

Risk Level: — NovoCure Ltd shows moderate risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate disclosure rather than immediate financial distress or significant new risks.

Analyst Insight

Review the executive compensation details and any shareholder proposals to understand management's incentives and potential changes in corporate strategy.

Key Numbers

• 2024-04-22 — Filing Date (Date the DEF 14A was filed)
• 2024-06-05 — Period of Report (The period this filing pertains to)
• 1231 — Fiscal Year End (The company's fiscal year end date)
• 3841 — SIC Code (Standard Industrial Classification for the company)

Key Players & Entities

• NovoCure Ltd (company) — Filer of the document
• DEF 14A (filing) — Type of document filed
• 2024-04-22 (date) — Filing date
• 2024-06-05 (date) — Period of report
• 3841 (other) — Standard Industrial Classification code

FAQ

Industry Context

NovoCure Ltd operates in the medical device sector, specifically focusing on surgical and medical instruments.

Regulatory Implications

The filing is a standard DEF 14A, subject to SEC regulations for public companies regarding disclosure of executive compensation and shareholder matters.

What Investors Should Do

1. Analyze executive compensation packages and any proposed changes.
2. Review shareholder proposals and voting recommendations.
3. Assess the company's corporate governance structure as detailed in the filing.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for public companies and does not represent a change from previous filings of the same type.

Key Financial Figures

• $509 million — ilding a profitable business Generated $509 million in annual net revenues. Invested a rec
• $223 million — annual net revenues. Invested a record $223 million in research and development initiatives
• $910 million — nts and short-term investments totaling $910 million at December 31, 2023. 6 Table of Con

Filing Documents

• nvcr-20240422.htm (DEF 14A) — 1727KB
• nvcr-20240422_g1.jpg (GRAPHIC) — 7KB
• nvcr-20240422_g2.jpg (GRAPHIC) — 2KB
• nvcr-20240422_g3.jpg (GRAPHIC) — 68KB
• nvcr-20240422_g4.jpg (GRAPHIC) — 252KB
• nvcr-20240422_g5.gif (GRAPHIC) — 59KB
• nvcr-20240422_g6.gif (GRAPHIC) — 58KB
• nvcr-20240422_g7.gif (GRAPHIC) — 57KB
• nvcr-20240422_g8.jpg (GRAPHIC) — 175KB
• nvcr-20240422_g9.jpg (GRAPHIC) — 498KB
• 0001645113-24-000011.txt (&nbsp;) — 5186KB
• nvcr-20240422.xsd (EX-101.SCH) — 1KB
• nvcr-20240422_htm.xml (XML) — 102KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 60 2023 Summary Compensation Table 60 2023 Grants of Plan-Based Awards 62 Outstanding Equity Awards at 2023 Fiscal Year End 64 Options Exercised and Stock Vested 66 Potential Payment upon Termination or Change in Control 66 Equity Compensation Plan Information 72 Pay Versus Performance 73 2023 PAY RATIO 77 INFORMATION ABOUT STOCK OWNERSHIP—SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 78 DELINQUENT SECTION 16(a) REPORTS 82 ADDITIONAL INFORMATION 82 Householding of Proxy Materials 82 Presentation of Accounts 82 Shareholder Proposals and Nominations for the 2025 Annual General Meeting of Shareholders 82 Other Matters 83 Annual Reports 83 Appendix A - NovoCure Limited 2024 Omnibus Incentive Plan A- 1 Table of Contents PROXY STATEMENT The Board of Directors (the "Board") of NovoCure Limited (the "Company", "Novocure", "we", "us" or "our") is soliciting your proxy to vote at our Annual General Meeting of Shareholders ("Annual Meeting") to be held on Wednesday, June 5, 2024, at 9:00 a.m. U.S. ET, at Second Floor, No. 4 The Forum, Grenville Street, St. Helier, Jersey, Channel Islands JE2 4UF, and any adjournment or postponement of that meeting. We have elected to provide access to our proxy materials on the Internet. Accordingly, we are sending a Notice of Internet Availability to holders of record of our ordinary shares ("Ordinary Shares") as of April 2, 2024 (the "Record Date"). All shareholders will have the ability to access the proxy materials on the website referred to in the Notice of Internet Availability, or to request a printed set of the proxy materials. Instructions on how to request a printed copy by mail or e-mail may be found in the Notice of Internet Availability and on the website referred to in the Notice of Internet Availability, including instructions on how to request paper copies on an ongoing basis. On or about April 22, 2024, we are making this Proxy S

EXECUTIVE COMPENSATION HIGHLIGHTS

EXECUTIVE COMPENSATION HIGHLIGHTS The primary objectives of our executive compensation program are to attract, retain and motivate superior executive talent, to provide incentives that reward the achievement of performance goals that we believe support the enhancement of shareholder value and to align the executives' interests with those of shareholders through long-term incentives. The following table highlights some of our executive compensation policies and practices, which are structured to drive performance and align our executives' interests with our shareholders' long-term interests: WHAT WE DO WHAT WE DON'T DO Pay for performance X No plans that encourage excessive risk Pay competitively X No share option repricing Align compensation with shareholder interests X No gross-ups in the event of a change in control Double trigger change in control provisions X No excessive perks Independent compensation consultant X No special health or welfare benefits Robust stock ownership and retention guidelines Clawback and recoupment policy Anti-hedging and anti-pledging policy Annual say-on-pay vote 7 Table of Contents THE PROXY PROCESS AND SHAREHOLDER VOTING QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING Who can vote at the Annual Meeting? Only shareholders of record at the close of business on the Record Date will be entitled to vote at the Annual Meeting. At the close of business on the Record Date, there were 107,606,309 Ordinary Shares issued and outstanding and entitled to vote. On each matter to be voted upon, you have one vote for each Ordinary Share you own as of the Record Date. What am I being asked to vote on? You are being asked to vote on three proposals: Proposal 1: To elect the ten directors named in this Proxy Statement to hold office for a one-year term expiring at our 2025 annual general meeting of shareholders or until their successors are duly elected and qualified or their offices are vacated; Proposal 2: To approve and

View Full Filing

View this DEF 14A filing on SEC EDGAR